Skip to main content
SpringerLink
Log in

Gastrointestinal Bleeding in Native and Prosthetic Valve Disease

  • Valvular Heart Disease (J Dal-Bianco, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Gastrointestinal bleeding with severe aortic stenosis was originally described in the 1950s by Heyde, although for years, the association was debated. Further discovery of mechanisms and the ubiquity and severity of acquired von Willebrand syndrome in the left ventricular assist device therapy have removed any doubts. At this time, gastrointestinal bleeding from intestinal angiodysplasia in patients with turbulence-related proteolysis of the highest molecular weight multimers of von Willebrand factor is now known to occur in patients with aortic stenosis, and also subaortic obstruction and associated mitral insufficiency in hypertrophic cardiomyopathy, isolated mitral and aortic insufficiency, endocarditis, and in patients with prosthetic valve dysfunction, either from stenosis or insufficiency. The degree of loss of high molecular weight multimers correlates with lesion severity, and tests of von Willebrand factor function have been proposed as important biomarkers of the severity of valve dysfunction, including in-lab testing for paravalvular leak during transcatheter aortic valve replacement. Bleeding tends to recur after endoscopic or surgical therapy, but cardiac repair is curative in the great majority.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Tiede A, Priesack J, Sersitzke S, Bohlmann K, Oortwijn B, Lenting P, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-center cohort study. J Thromb Haem. 2008;6(4):569–76. https://doi.org/10.1111/j.1538-7836.2008.02909.x.

  2. Studt JD, Budde U, Schneppenheim R, Eisert R, von Depka Prondzinski M, Ganser A, et al. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. Am J Clin Pathol. 2001;116(4):567–74. https://doi.org/10.1309/75CQ-V7UX-4QX8-WXE7.

  3. Lippok S, Obser T, Muller JP, Stierle VK, Benoit M, Budde U, et al. Exponential size distribution of von Willebrand factor. Biphysical J. 2013;105(5):1208–16. https://doi.org/10.1016/j.bpj.2013.07.037.

  4. Lenting P, Casari C, Christophe OD, Denis CV. Von Willebrand factor: the old, the new, and the unknown. J Thromb Haemaost. 2012;10(12):2428–37. https://doi.org/10.1111/jth.12008.

    Article  CAS  Google Scholar 

  5. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TAJ, Sutton RE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071–80. https://doi.org/10.1182/blood-2010-01-264507.

  6. Franchini M, Mannucci PM. Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol. 2013;16:177–82.

    Article  Google Scholar 

  7. •• Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015;116(7):1193–201. https://doi.org/10.1161/CIRCRESAHA.116.305046. An important contribution to the conceptual literature demonstrating the utility of multiple VWF measures in a variety of clinical and laboratory settings. Among the entities investigated are a rabbit model of aortic stenosis, time course of onset of VWF abnormalities after insertion of left ventricular assist devices, and an introduction to the utility of VWF measures in assessing acute hemodynamic status of transcatheter aortic valve insertion.

  8. Blackshear JL, Kusumoto H, Safford RE, Wysokinska E, Thomas CS, Waldo OA, et al. Usefulness of von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy. Am J Cardiol. 2015;117(3):436–42. https://doi.org/10.1016/j.amjcard.2015.11.016.

  9. •• Blackshear JL, McRee CW, Safford RE, Pollak PM, Stark ME, Thomas CS, et al. Von Willebrand factor abnormalities and Heyde syndrome in dysfunctional heart valve prostheses. JAMA Cardiol. 2016;1(2):198–204. https://doi.org/10.1001/jamacardio.2016.0075. This paper contains the only values of VWF functional tests in the literature regarding mild, moderate, and moderate to severe native aortic regurgitation. It also demonstrated the utility of VWF measures as markers of pathologic change in late prosthetic valve dysfunction.

  10. •• Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, et al. Von Willebrand factor multimers during transcatheter aortic valve replacement. N Engl J Med. 2016;375(4):335–44. https://doi.org/10.1056/NEJMoa1505643. This paper complements the prior study by demonstrating that acute prosthesis dysfunction, as occurs from paravalvular aortic regurgitation, is also associated with failure of correction of VWF abnormalities associated with aortic stenosis. Also, VWF measures were used acutely (PFA-100) as a point of care test to dictate whether additional balloon inflations or retrieval and deployment of a different prosthesis should be undertaken. This is the first demonstration of “real time” utilization of VWF tests in clinical management.

  11. Blackshear J, Wysokinska E, Safford R, Thomas C, Stark M, Shapiro B, et al. Indexes of von Willebrand factor as biomarkers of aortid stenosis severity (from the biomarkers of aortic stenosis severity [BASS] study). J Cardiol. 2013;111:374–81.

  12. Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood. 1988;71(6):1648–55.

    CAS  PubMed  Google Scholar 

  13. Chen YC, Yang L, Cheng SN, Hu SH, Chao TY. Von Willebrand disease: a clinical and laboratory study of 65 patients. Ann Hematol. 2011;90(10):1183–90. https://doi.org/10.1007/s00277-011-1266-4.

    Article  PubMed  Google Scholar 

  14. Weiss, DR, Strasser DF, Ringwald J, et al. High resolution multimer analysis and the PFA-100 platelet function analyzer can detect von Willebrand disease type 2A without a patholocial ratio of ristocetin cofactor activity and von Willebrand antigen level. Clin Lab 2012;58(11-12):1203–9

  15. Cody MC, O’Donovan TP, Hughes RW Jr. Idiopathic gastrointestinal bleeding and aortic stenosis. Am J Dig Dis. 1974;19(5):393–8. https://doi.org/10.1007/BF01255601.

    Article  CAS  PubMed  Google Scholar 

  16. Roges BH. Endoscopic diagnosis and therapy on mucosal vascular abnormalities of the gastrointestinal tract occurring in elderly patients and associated with cardiac, vascular, and pulmonary disease. Gastrointest Endosc. 1980;26:134–8.

    Article  Google Scholar 

  17. Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(4):474–83. https://doi.org/10.1038/ajg.2014.19.

    Article  PubMed  Google Scholar 

  18. King RM, Pluth JR, Giuliani ER. The association of junexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg. 1987;44(5):514–6. https://doi.org/10.1016/S0003-4975(10)62112-1.

    Article  CAS  PubMed  Google Scholar 

  19. Thompson JL, Schaff HV, Dearani JA, Park SJ, Tundy TM, Suri RM, et al. Risk of recurrent gastrointestinal bleeding after aortic valve replacement in patients with Heyde syndrome. J Thorac Cardiovasc Surg. 2012;144(1):112–6. https://doi.org/10.1016/j.jtcvs.2011.05.034.

  20. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343–9. https://doi.org/10.1056/NEJMoa022831.

  21. Yoshida K, Tobe S, Kawata M, Yamaguchi M. Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis. Ann Thorac Surg. 2006;81(2):490–4. https://doi.org/10.1016/j.athoracsur.2005.07.074.

    Article  PubMed  Google Scholar 

  22. Sucker C, Feindtz P, Zotzi RB, Stockschlaeder M, Scharf RE. Functional von Willebrand factor assays are not predictive for the absence of highest-molecular weight von Willebrand factor multimers in patients with aortic-valve stenosis. Thromb Haemost. 2005;94(2):465–6.

    CAS  PubMed  Google Scholar 

  23. Casonato A, Sponga S, Pontara E. Von Willbrand factor abnormalities in aortic valve stensosis: pathophysiology and impact on bleeding. Throm Haemost. 2011;106(1):58–66. https://doi.org/10.1160/TH10-10-0634.

    Article  CAS  Google Scholar 

  24. Solomon C, Budde U, Schneppenheim S. Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. Br J Anaesth. 2011;106(4):494–500. https://doi.org/10.1093/bja/aeq413.

    Article  CAS  PubMed  Google Scholar 

  25. Godino C, Lauretta L, Pavon AG, Mangieri A, Viani G, Chieffo A, et al. Heyde’s syndrome incidence and outcome in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;61(6):687–9. https://doi.org/10.1016/j.jacc.2012.10.041.

  26. Caspar T, Jesel L, Desprez D, Grunebaum L, Samet H, Trinh A, et al. Effects of transcutaneous aortic valve implantation on aortic valve disease-related emostatic disroders involving von Willebrand factor. Can J Cardiol. 2015;31(6):738–43. https://doi.org/10.1016/j.cjca.2015.01.012.

  27. Guha A, Eshelbrenner CL, Richards DM, Monsour HP Jr. Gastrointestinal bleeding after continuous flow left ventricular device implanation: review of pathophysiology and management. Method Debakey Cardiovasc J. 2015;11:24–7.

    Article  Google Scholar 

  28. Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a sinfle laboratory compared with data from the literature and an international registry. Semin Thromb Haemost. 2002;28(2):227–38. https://doi.org/10.1055/s-2002-27824.

    Article  CAS  Google Scholar 

  29. Wan SH, Liang JJ, Vaidya R, Blackshear JL, Chen D. Acquired von Willebrand syndrome secondary to mitral and aortic regurgitation. Can J Cardiol. 2014;30:1108 e9–1108 e10.

    Article  Google Scholar 

  30. Blackshear JL, Wysokinska EM, Safford RE, Thomas CS, Shapiro BP, Ung S, et al. Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation. J Thromb Haemost. 2014;12(12):1966–74. https://doi.org/10.1111/jth.12734.

  31. Le Tourneau TL, Susen S, Caron C, Millaire S, Ennezat PV, Lamblin N, et al. Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation. 2008;118(15):1550–7. https://doi.org/10.1161/CIRCULATIONAHA.108.786681.

  32. Blackshear JL, Schaff HV, Ommen SR, Chen D, Nichols WL Jr. Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willbrand syndrome: response to septal myectomy. Mayo Clin Proc. 2011;86(3):219–24. https://doi.org/10.4065/mcp.2010.0309.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Blackshear JL, Stark ME, Agnew RC, Moussa IM, Safford RE, Shapiro BP, et al. Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome. J Thromb Haemost. 2015;13(2):191–6. https://doi.org/10.1111/jth.12780.

  34. Perez-Rodriguez A, Pinto JC, Loures E, et al. Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study. Eur J Haematol. 2011;87(5):448–56. https://doi.org/10.1111/j.1600-0609.2011.01664.x.

    Article  CAS  PubMed  Google Scholar 

  35. Makkar RR, Fontana G, Julaihaw H, et al. Possible subclinical valve thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24. https://doi.org/10.1056/NEJMoa1509233.

    Article  CAS  PubMed  Google Scholar 

  36. Spangenbeg T, Budde U, Schewel, et al. Loss of high molecular weight multimers of von Willebrand factor in aortic stenosis with transcatheter aortic valve replacement (TAVR). JACC Cardiovasc Interv. 2016;8(5):692–700.

    Article  Google Scholar 

  37. Genereaux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64(24):2605–16. https://doi.org/10.1016/j.jacc.2014.08.052.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Diseases, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Joseph L. Blackshear MD

Authors
  1. Joseph L. Blackshear MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph L. Blackshear MD.

Ethics declarations

Conflict of Interest

Joseph L. Blackshear reports a research grant from Baxalta Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Valvular Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blackshear, J.L. Gastrointestinal Bleeding in Native and Prosthetic Valve Disease. Curr Treat Options Cardio Med 20, 6 (2018). https://doi.org/10.1007/s11936-018-0595-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-018-0595-1

Keywords

Search

Navigation